1. Sansone V, Meola G, Links TP, et al. Treatment for periodic paralysis. Cochrane Database Syst Rev. 2008. doi: 10.1002/14651858.CD005045.pub2 .
2. Platt D, Griggs R. Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. Curr Opin Neurol. 2009;22(5):524–31.
3. Statland JM, Barohn RJ. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses. Continuum. 2013;19(6 Muscle Disease):1598–614.
4. Taro Pharmaceuticals USA Inc. Keveyis™ (dichlorphenamide) tablets, for oral use: US prescribing information. 2015. http://www.fda.gov . Accessed 25 Feb 2016.
5. Taro Pharmaceuticals Industries Ltd. FDA approves Keveyis (dichlorphenamide) for primary hyperkalemic and hypokalemic periodic paralysis [media release]. 10 Aug 2015. http://www.drugs.com/newdrugs .